Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in ...

Omeros has announced that the activation of clinical trial sites for patient enrolment is now in progress for its Phase III programme of the human monoclonal antibody zaltenibart for treating ...

Omeros (NASDAQ:OMER – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Monday, April 7th. Analysts expect Omeros to post earnings of ($0.71) per share ...

SEATTLE, April 10, 2025--Omeros Corporation (Nasdaq: OMER) today announced the establishment of the Omeros Oncology Clinical Steering Committee to advance Omeros’ OncotoX biologics program ...

We are pleased to announce that our narsoplimab BLA for the treatment of TA-TMA was resubmitted to FDA earlier this month, with the MAA slated ...

Omeros (NASDAQ:OMER – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at D. Boral Capital in a note issued to investors on Tuesday,Benzinga reports. They presently have ...

Seattle-based biotech company Curi Bio has settled into its new 13,942-square-foot space in Interbay. The company moved to ...

Needham analyst Serge Belanger maintained a Hold rating on Omeros (OMER – Research Report) today. The company’s shares opened today at ...

SEATTLE (AP) — SEATTLE (AP) — Omeros Corporation (OMER) on Monday reported a loss of $31.4 million in its fourth quarter. The Seattle-based company said it had a loss of 54 cents per share. Losses, ...

OMEROS ($OMER) posted quarterly earnings results on Monday, March 31st. The company reported earnings of -$0.63 per share, beating estimates of -$0.68 by $0.05. The ...